Ting Therapeutics

Executive Summary

Ting Therapeutics is a preclinical-stage biotechnology company focused on developing a first-in-class small molecule therapy to prevent aminoglycoside-induced hearing loss. Aminoglycoside antibiotics, such as gentamicin and amikacin, are essential for treating severe infections but cause permanent hearing loss in 20–25% of patients. No FDA-approved prophylactic or therapeutic options currently exist. The company’s lead candidate targets a novel mechanism distinct from conventional antioxidant approaches, potentially offering superior efficacy and safety. Preclinical studies have demonstrated significant protection against ototoxicity in animal models, with a favorable pharmacokinetic profile. Founded in 2019 and based in San Diego, Ting Therapeutics is advancing its program toward Investigational New Drug (IND)-enabling studies. The company aims to address a significant unmet medical need affecting over 360 million people worldwide, with initial focus on oncology patients receiving aminoglycoside chemotherapy. With a lean operation and a clear regulatory pathway, the company is positioned to attract partnership or funding for clinical translation.

Upcoming Catalysts (preview)

• Q4 2026Completion of IND-enabling toxicology studies70% success
• Q1 2027Filing of IND application with FDA60% success
• Q3 2027Initial Phase I clinical trial results40% success